STOCK TITAN

Redhill Biopharm Stock Price, News & Analysis

RDHL Nasdaq

Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.

RedHill Biopharma Ltd (NASDAQ: RDHL) is a specialty biopharmaceutical leader focused on gastrointestinal and infectious disease therapies. This page provides investors and industry professionals with comprehensive updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.

Access real-time announcements including FDA submissions, clinical trial results, and partnership agreements. Track progress across RedHill’s commercial products like Talicia for H. pylori and Aemcolo for travelers’ diarrhea, along with late-stage candidates such as opaganib in oncology and inflammatory diseases.

Our curated news collection enables informed decision-making by consolidating material events including earnings reports, intellectual property updates, and research collaborations. Content spans therapeutic area breakthroughs, management commentary, and market expansion activities.

Bookmark this page for streamlined access to verified RedHill Biopharma updates. Check regularly for developments impacting the company’s position in gastrointestinal therapeutics and pandemic preparedness research.

Rhea-AI Summary

RedHill Biopharma has licensed RHB-102 (Bekinda®) to Hyloris Pharmaceuticals for commercialization worldwide excluding North America. The deal includes an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues.

RHB-102 is a once-daily, extended-release oral tablet formulation of ondansetron in development for multiple indications. The UK MHRA has provided a clear pathway for a Marketing Authorization Application, potentially making it the first oral 24-hour extended-release ondansetron for treating chemotherapy/radiotherapy-induced nausea and vomiting.

RedHill will continue development for FDA approval in the U.S., while Hyloris handles development, regulatory and commercialization activities in its territories. The global antiemetics market was valued at approximately $7.5 billion in 2023 with expected growth at 6% CAGR through 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.83%
Tags
none
-
Rhea-AI Summary

RedHill Biopharma has initiated a Phase 2 clinical study evaluating opaganib combined with Bayer's darolutamide for metastatic castrate-resistant prostate cancer (mCRPC). The 80-patient placebo-controlled study, financially supported by Bayer and Ramsay Hospital Research Foundation, will be led by Professor Lisa Horvath from Chris O'Brien Lifehouse and ANZUP.

The study will use a companion lipid biomarker test (PCPro) to select mCRPC patients with poor prognosis from standard treatment. The primary endpoint is improved 12-month radiographic progression-free survival. The research aims to overcome resistance to standard androgen receptor pathway inhibition treatment.

Prostate cancer, the second most diagnosed cancer globally with 1.5 million new cases annually and 400,000 deaths, represents a $12 billion market. The study's approach of developing therapeutic combinations with the PCPro biomarker is unique in metabolic targeting for metastatic prostate cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
-
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) announced two significant developments for its H. pylori treatment Talicia®. First, Humana's Part D Plan now covers Talicia, providing access to over 8 million additional Medicare beneficiaries without requiring prior therapeutic steps or authorization, effective January 1, 2025.

Additionally, new data published in The Journal of Clinical Pharmacology supports Talicia's FDA-approved label change to a more convenient three-times daily (TID) dosing schedule with meals. The study demonstrated pharmacokinetic equivalence between the new TID regimen and the previous every 8-hour (Q8H) dosing schedule.

Talicia continues to be the most prescribed branded H. pylori therapy by U.S. gastroenterologists and is listed as a first-line treatment option in the updated American College of Gastroenterology Clinical Guideline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.3%
Tags
none
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) announced positive results from new in vivo studies of opaganib for treating gastrointestinal acute radiation syndrome (GI-ARS). The studies were conducted under the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP) contract and confirmed opaganib's protective activity.

The company is in discussions with the National Institute of Allergy and Infectious Diseases (NIAID) regarding the next development phase following the FDA's Animal Rule pathway. Opaganib, an oral small molecule with a five-year shelf-life, is being developed as a potential medical countermeasure for GI-ARS, for which there are currently no approved therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.77%
Tags
none
-
Rhea-AI Summary

RedHill Biopharma has been awarded approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. The amount consists of $6.5 million plus interest of approximately $1.5 million. The case involves Kukbo's failure to make agreed payments to RedHill under a Subscription Agreement from October 25, 2021, and an Exclusive License Agreement from March 14, 2022. The Court dismissed all of Kukbo's counterclaims. Kukbo retains the right to seek an appeal of the judgment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) has been selected to present its drug opaganib at the JPEO-CBRND's 'Host Directed Therapeutics Industry Day' on October 29-30, 2024, in Alexandria, VA. The selection was based on the drug's demonstrated capabilities in prophylaxis and treatment of exposure to viruses, bacteria, and toxins.

The JPEO-CBRND, which manages U.S. government investments in chemical, biological, radiological, and nuclear defense equipment and medical countermeasures, will host the presentation. Opaganib, a novel host-directed oral drug, is being developed for various applications including oncology, viral infections, inflammatory diseases, and chemical/nuclear protection, with multiple ongoing U.S. government collaborations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) has announced a collaboration with Duke University School of Medicine to develop opaganib as a potential countermeasure against phosgene inhalation injury. The research aims to advance opaganib into U.S. government-sponsored development under the FDA's Animal Rule pathway to approval.

Phosgene, a toxic chemical used in industrial processes, poses a significant risk to public safety. The EPA has identified 123 sites in the U.S. that could potentially expose millions to phosgene. Currently, there is no approved antidote for phosgene inhalation injury, which can cause severe respiratory damage.

Opaganib, RedHill's novel, host-directed drug, is being developed for various indications, including chemical and nuclear/radioprotection. The collaboration with Duke University aims to determine if opaganib can provide protection against phosgene-induced damage and potentially be stockpiled for emergency use.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
Rhea-AI Summary

RedHill Biopharma has secured U.S. government funding through BARDA to advance opaganib for Ebola treatment. The funding will support the development of opaganib as a medical countermeasure (MCM) for Ebola virus disease (EBOV). Recent U.S. Army-funded studies showed that opaganib significantly increased survival in an EBOV model. Opaganib is a novel, potentially broad-acting drug with mutation-resistant antiviral and anti-inflammatory activity.

The development comes as there is an urgent need for effective and usable therapies for EBOV, which has a fatality rate of around 50% according to WHO. Opaganib represents an alternative host-directed therapeutic strategy for biodefense and global health preparedness. The drug is also being developed for other indications, including COVID-19, ARDS, and radiological and chemical protection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) has renewed its contract with Medi-Cal, California's Medicaid healthcare program, to maintain Talicia's first-line position on the Medi-Cal Fee-For-Service (FFS) Contract Drug List with no prior authorization and a $0 copay. This renewal, effective October 1, 2024, benefits approximately 15 million Californian Medi-Cal patients.

The agreement follows the new American College of Gastroenterology (ACG) Clinical Guideline for H. pylori infection, which lists Talicia as an empirically prescribed first-line option. Talicia's all-in-one three-times daily formulation offers a simplified patient experience, supporting high rates of H. pylori eradication without requiring prior resistance testing. It remains the most prescribed branded H. pylori therapy by U.S. gastroenterologists.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
none
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) has announced the issuance of a new U.S. patent for opaganib, valid through 2041. The patent covers the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-19.

Post-hoc data from opaganib's Phase 2/3 study showed that patients with ≤60% FiO2 levels had better outcomes after 14 days of treatment compared to placebo, including:

  • Increased number of patients no longer requiring supplemental oxygen (76.9% vs. 63.4%; p-value=0.033)
  • 62.6% reduction in intubation/mechanical ventilation (6.84% vs. 17.91%; p-value=0.012)
  • 62% reduction in mortality by day 42 (5.98% vs. 16.7%; p-value=0.019)

Opaganib is being developed for various indications, including oncology, viral infections, inflammatory diseases, and nuclear/radioprotection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none

FAQ

What is the current stock price of Redhill Biopharm (RDHL)?

The current stock price of Redhill Biopharm (RDHL) is $2.03 as of July 3, 2025.

What is the market cap of Redhill Biopharm (RDHL)?

The market cap of Redhill Biopharm (RDHL) is approximately 4.2M.
Redhill Biopharm

Nasdaq:RDHL

RDHL Rankings

RDHL Stock Data

4.17M
1.77M
6.77%
2.62%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Tel Aviv